Chinese General Practice ›› 2023, Vol. 26 ›› Issue (36): 4545-4551.DOI: 10.12114/j.issn.1007-9572.2023.0193
Special Issue: 肿瘤最新文章合集; 肺癌最新文章合集
• Article • Previous Articles Next Articles
Received:
2023-01-20
Revised:
2023-05-06
Published:
2023-12-20
Online:
2023-06-07
Contact:
LIU Junyan, HAN Ying
通讯作者:
刘俊艳, 韩颖
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0193
组别 | 例数 | 年龄(岁) | 性别〔例(%)〕 | BMI (kg/m2) | 既往史〔例(%)〕 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 高血压 | CAHD | 2型糖尿病 | 脑梗死 | 心房颤动 | 高脂血症 | 主动吸烟史 | 饮酒史 | ||||
对照组 | 126 | 63.8±6.7 | 72(57.14) | 54(42.86) | 24.6±3.3 | 56(44.44) | 13(10.32) | 14(11.11) | 15(11.90) | 0 | 7(5.56) | 37(29.37) | 34(26.98) |
病例组 | 25 | 63.7±8.9 | 15(60.00) | 10(40.00) | 23.3±3.6 | 10(40.00) | 6(24.00) | 5(20.00) | 2(8.00) | 1(4.00) | 0 | 11(44.00) | 10(40.00) |
检验统计量值 | 0.083a | 0.070 | 1.724a | 0.168 | 3.051 | 1.344 | 0.344 | 3.631c | 2.601c | 2.061 | 1.712 | ||
P值 | 0.934 | 0.792 | 0.087 | 0.682 | 0.092 | 0.317 | 0.74 | 0.166 | 0.601 | 0.151 | 0.191 | ||
组别 | 用药史〔例(%)〕 | 术前化疗〔例(%)〕 | 白细胞计数(×109/L) | 红细胞计数(×1012/L) | 血红蛋白(g/L) | 血小板计数(×109/L) | |||||||
抗血小板聚集药 | 他汀类 | ||||||||||||
对照组 | 18(14.40) | 11(8.73) | 2(1.59) | 5.94±1.96 | 4.60±0.42 | 141.54±14.49 | 231.88±63.05 | ||||||
病例组 | 3(12.00) | 3(12.00) | 3(12.00) | 6.89±2.21 | 4.45±0.51 | 136.96±14.35 | 225.76±52.30 | ||||||
检验统计量值 | 0.103 | 0.249 | 5.024 | -2.164a | 1.482a | 1.446a | 0.455a | ||||||
P值 | 1.000 | 0.704 | 0.032 | 0.032 | 0.140 | 0.150 | 0.650 | ||||||
组别 | D-二聚体〔M(P25,P75),mg/L〕 | 纤维蛋白原(g/L) | eGFR 〔mL·min-1·(1.73 m2)-1〕 | SUA (μmol/L) | 血肌酐(μmol/L) | 总胆固醇(mmol/L) | 颅内外大动脉狭窄〔例(%)〕 | ||||||
对照组 | 0.10(0.06,0.18) | 2.95±0.62 | 97.42±9.54 | 326.06±80.47 | 59.90±12.22 | 4.98±1.02 | 9(11.39) | ||||||
病例组 | 0.14(0.07,0.21) | 3.32±0.84 | 98.64±12.21 | 286.86±79.40 | 59.14±14.28 | 5.20±1.18 | 4(33.33) | ||||||
检验统计量值 | -1.655b | -2.576a | -0.556a | 2.230a | 0.266a | -0.782a | 3.331 | ||||||
P值 | 0.098 | 0.011 | 0.579 | 0.027 | 0.790 | 0.436 | 0.065 |
Table 1 Comparison of baseline clinical characteristics between the case group and control group
组别 | 例数 | 年龄(岁) | 性别〔例(%)〕 | BMI (kg/m2) | 既往史〔例(%)〕 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 高血压 | CAHD | 2型糖尿病 | 脑梗死 | 心房颤动 | 高脂血症 | 主动吸烟史 | 饮酒史 | ||||
对照组 | 126 | 63.8±6.7 | 72(57.14) | 54(42.86) | 24.6±3.3 | 56(44.44) | 13(10.32) | 14(11.11) | 15(11.90) | 0 | 7(5.56) | 37(29.37) | 34(26.98) |
病例组 | 25 | 63.7±8.9 | 15(60.00) | 10(40.00) | 23.3±3.6 | 10(40.00) | 6(24.00) | 5(20.00) | 2(8.00) | 1(4.00) | 0 | 11(44.00) | 10(40.00) |
检验统计量值 | 0.083a | 0.070 | 1.724a | 0.168 | 3.051 | 1.344 | 0.344 | 3.631c | 2.601c | 2.061 | 1.712 | ||
P值 | 0.934 | 0.792 | 0.087 | 0.682 | 0.092 | 0.317 | 0.74 | 0.166 | 0.601 | 0.151 | 0.191 | ||
组别 | 用药史〔例(%)〕 | 术前化疗〔例(%)〕 | 白细胞计数(×109/L) | 红细胞计数(×1012/L) | 血红蛋白(g/L) | 血小板计数(×109/L) | |||||||
抗血小板聚集药 | 他汀类 | ||||||||||||
对照组 | 18(14.40) | 11(8.73) | 2(1.59) | 5.94±1.96 | 4.60±0.42 | 141.54±14.49 | 231.88±63.05 | ||||||
病例组 | 3(12.00) | 3(12.00) | 3(12.00) | 6.89±2.21 | 4.45±0.51 | 136.96±14.35 | 225.76±52.30 | ||||||
检验统计量值 | 0.103 | 0.249 | 5.024 | -2.164a | 1.482a | 1.446a | 0.455a | ||||||
P值 | 1.000 | 0.704 | 0.032 | 0.032 | 0.140 | 0.150 | 0.650 | ||||||
组别 | D-二聚体〔M(P25,P75),mg/L〕 | 纤维蛋白原(g/L) | eGFR 〔mL·min-1·(1.73 m2)-1〕 | SUA (μmol/L) | 血肌酐(μmol/L) | 总胆固醇(mmol/L) | 颅内外大动脉狭窄〔例(%)〕 | ||||||
对照组 | 0.10(0.06,0.18) | 2.95±0.62 | 97.42±9.54 | 326.06±80.47 | 59.90±12.22 | 4.98±1.02 | 9(11.39) | ||||||
病例组 | 0.14(0.07,0.21) | 3.32±0.84 | 98.64±12.21 | 286.86±79.40 | 59.14±14.28 | 5.20±1.18 | 4(33.33) | ||||||
检验统计量值 | -1.655b | -2.576a | -0.556a | 2.230a | 0.266a | -0.782a | 3.331 | ||||||
P值 | 0.098 | 0.011 | 0.579 | 0.027 | 0.790 | 0.436 | 0.065 |
组别 | 例数 | 手术方式〔例(%)〕 | 切除部位〔例(%)〕 | 手术持续时间(min) | 麻醉持续时间(min) | |||||
---|---|---|---|---|---|---|---|---|---|---|
开胸 | 胸腔镜 | LUL或LP | 其他 | |||||||
对照组 | 126 | 1(0.79) | 125(99.21) | 38(30.16) | 88(69.84) | 144.75±45.07 | 198.11±46.50 | |||
病例组 | 25 | 3(12.00) | 22(88.00) | 10(40.00) | 15(60.00) | 173.60±58.21 | 237.20±62.15 | |||
χ2(t)值 | 10.159 | 0.932 | -2.778a | -3.617a | ||||||
P值 | 0.001 | 0.334 | 0.006 | <0.001 | ||||||
组别 | 术中血压参数(mmHg) | 病理类型〔例(%)〕 | 疾病分期〔例(%)〕 | 脉管侵犯〔例(%)〕 | 脏层胸膜受侵〔例(%)〕 | |||||
最大SBP | 最小SBP | 平均SBP | SBP CV | 腺癌 | 鳞癌 | 早期 | 晚期 | |||
对照组 | 141±13 | 107±9 | 122±8 | 7.08±2.67 | 111(88.10) | 15(11.90) | 118(93.65) | 8(6.35) | 2(1.59) | 11(8.73) |
病例组 | 138±14 | 108±13 | 122±11 | 5.83±3.09 | 19(76.00) | 6(24.00) | 20(80.00) | 5(20.00) | 2(8.00) | 6(24.00) |
χ2(t)值 | 1.328a | -0.514a | -0.117a | 2.086a | 2.549 | 4.941 | 2.462 | 4.059 | ||
P值 | 0.186 | 0.608 | 0.907 | 0.039 | 0.110 | 0.026 | 0.128 | 0.039 |
Table 2 Surgical and pathology-related indicators
组别 | 例数 | 手术方式〔例(%)〕 | 切除部位〔例(%)〕 | 手术持续时间(min) | 麻醉持续时间(min) | |||||
---|---|---|---|---|---|---|---|---|---|---|
开胸 | 胸腔镜 | LUL或LP | 其他 | |||||||
对照组 | 126 | 1(0.79) | 125(99.21) | 38(30.16) | 88(69.84) | 144.75±45.07 | 198.11±46.50 | |||
病例组 | 25 | 3(12.00) | 22(88.00) | 10(40.00) | 15(60.00) | 173.60±58.21 | 237.20±62.15 | |||
χ2(t)值 | 10.159 | 0.932 | -2.778a | -3.617a | ||||||
P值 | 0.001 | 0.334 | 0.006 | <0.001 | ||||||
组别 | 术中血压参数(mmHg) | 病理类型〔例(%)〕 | 疾病分期〔例(%)〕 | 脉管侵犯〔例(%)〕 | 脏层胸膜受侵〔例(%)〕 | |||||
最大SBP | 最小SBP | 平均SBP | SBP CV | 腺癌 | 鳞癌 | 早期 | 晚期 | |||
对照组 | 141±13 | 107±9 | 122±8 | 7.08±2.67 | 111(88.10) | 15(11.90) | 118(93.65) | 8(6.35) | 2(1.59) | 11(8.73) |
病例组 | 138±14 | 108±13 | 122±11 | 5.83±3.09 | 19(76.00) | 6(24.00) | 20(80.00) | 5(20.00) | 2(8.00) | 6(24.00) |
χ2(t)值 | 1.328a | -0.514a | -0.117a | 2.086a | 2.549 | 4.941 | 2.462 | 4.059 | ||
P值 | 0.186 | 0.608 | 0.907 | 0.039 | 0.110 | 0.026 | 0.128 | 0.039 |
观察指标 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
术前化疗 | 2.135 | 0.942 | 5.138 | 8.455(1.335,53.541) | 0.023 |
高血压 | -0.182 | 0.446 | 0.167 | 0.833(0.348,1.997) | 0.683 |
2型糖尿病 | 0.693 | 0.575 | 1.454 | 2.000(0.648,6.170) | 0.228 |
颅内外大动脉狭窄 | 1.358 | 0.707 | 3.687 | 3.889(0.972,15.560) | 0.055 |
白细胞计数 | 0.201 | 0.097 | 4.311 | 1.223(1.011,1.479) | 0.038 |
纤维蛋白原 | 0.740 | 0.304 | 5.935 | 2.097(1.156,3.804) | 0.015 |
SUA | -0.007 | 0.003 | 4.718 | 0.993(0.987,0.999) | 0.030 |
手术方式 | |||||
开胸 | 2.836 | 1.178 | 5.799 | 17.045(1.695,171.395) | 0.016 |
手术持续时间 | 0.012 | 0.004 | 6.833 | 1.012(1.003,1.020) | 0.009 |
麻醉持续时间 | 0.015 | 0.005 | 10.227 | 1.015(1.006,1.024) | 0.001 |
脏层胸膜受侵 | 1.194 | 0.565 | 4.473 | 3.301(1.092,9.986) | 0.034 |
疾病分期 | |||||
晚期 | 1.305 | 0.619 | 4.441 | 3.688(1.096,12.412) | 0.035 |
Table 3 Univariate Logistic regression analysis of the influencing factors of POAIS in patients with NSCLC
观察指标 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
术前化疗 | 2.135 | 0.942 | 5.138 | 8.455(1.335,53.541) | 0.023 |
高血压 | -0.182 | 0.446 | 0.167 | 0.833(0.348,1.997) | 0.683 |
2型糖尿病 | 0.693 | 0.575 | 1.454 | 2.000(0.648,6.170) | 0.228 |
颅内外大动脉狭窄 | 1.358 | 0.707 | 3.687 | 3.889(0.972,15.560) | 0.055 |
白细胞计数 | 0.201 | 0.097 | 4.311 | 1.223(1.011,1.479) | 0.038 |
纤维蛋白原 | 0.740 | 0.304 | 5.935 | 2.097(1.156,3.804) | 0.015 |
SUA | -0.007 | 0.003 | 4.718 | 0.993(0.987,0.999) | 0.030 |
手术方式 | |||||
开胸 | 2.836 | 1.178 | 5.799 | 17.045(1.695,171.395) | 0.016 |
手术持续时间 | 0.012 | 0.004 | 6.833 | 1.012(1.003,1.020) | 0.009 |
麻醉持续时间 | 0.015 | 0.005 | 10.227 | 1.015(1.006,1.024) | 0.001 |
脏层胸膜受侵 | 1.194 | 0.565 | 4.473 | 3.301(1.092,9.986) | 0.034 |
疾病分期 | |||||
晚期 | 1.305 | 0.619 | 4.441 | 3.688(1.096,12.412) | 0.035 |
观察指标 | SUA | 高血压 | 2型糖尿病 | 颅内外大动脉狭窄 |
---|---|---|---|---|
SUA | 1 | — | — | — |
高血压 | 0.204a | 1 | — | — |
2型糖尿病 | -0.064 | 0.229a | 1 | — |
颅内外大动脉狭窄 | -0.022 | 0.162 | 0.326a | 1 |
Table 4 Correlation analysis of SUA with hypertension,type 2 diabetes mellitus,intracranial and extracranial large artery stenosis
观察指标 | SUA | 高血压 | 2型糖尿病 | 颅内外大动脉狭窄 |
---|---|---|---|---|
SUA | 1 | — | — | — |
高血压 | 0.204a | 1 | — | — |
2型糖尿病 | -0.064 | 0.229a | 1 | — |
颅内外大动脉狭窄 | -0.022 | 0.162 | 0.326a | 1 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] | |
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
苑杰,路月英,郭鑫,等. 血清尿酸水平对急性缺血性脑卒中后抑郁的预测价值研究[J]. 中国全科医学,2018,21(16):1974-1979. DOI:10.3969/j.issn.1007-9572.2018.16.014.
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[1] | HE Jia, LI Yongping, WEI Feng, LIU Meilan, WU Yaling, SHAO Longge. Correlation of lncRNA NEAT1 and miRNA-182-5p with the Risk of Liver Fibrosis in Type 2 Diabetes Mellitus Patients with MAFLD [J]. Chinese General Practice, 2024, 27(03): 300-307. |
[2] | LIN Xiaomei, ZUMURETI Abudukiyimu, MA Chunhui, XU Mengge, MA Juxing, LI Xia. Study on the Correlation of Serum Interleukin-6 and Fasting Blood Glucose with Coronary Heart Disease and Adverse Cardiovascular Events [J]. Chinese General Practice, 2024, 27(03): 286-292. |
[3] | WU Ruipeng, PENG Cheng, YUAN Bingkun, ZHANG Mengjun, LI Wenyuan. Correlation between Serum Uric Acid to High-density Lipoprotein Cholesterol Ratio and Metabolic Syndrome in Middle-aged and Elderly Population in China [J]. Chinese General Practice, 2024, 27(03): 293-299. |
[4] | LIN Lingjun, GUO Jun, WANG Junwei, GAO Yang, CHEN Huiying, WAN Yongli. A Systematic Review of Risk Prediction Models for Diabetic Foot Development [J]. Chinese General Practice, 2024, 27(03): 357-363,380. |
[5] | YANG Ji, ZHANG Yao, MA Teng, TIAN Xintong, ZHAO Yingqiang. Epidemic Status, Disease Burden and Prediction of Cardiovascular Diseases in China, 1990-2019 [J]. Chinese General Practice, 2024, 27(02): 233-244,252. |
[6] | HU Qianqian, ZHOU Tong, LIU Zhihui, PAN Ye, WANG Liuyi. Analysis of the Current Status of Ischemic Stroke Co-morbidity and Co-morbidity Patterns in Middle-aged Based on Data from Tertiary Hospitals in Henan Province [J]. Chinese General Practice, 2024, 27(02): 201-207. |
[7] | ZHOU Jing, JIA Jianguo, LIN Yixin, WU Shuang, DAI Shilong, WANG Mingjun, ZHANG Qingsong. Association of Different Metabolic Obesity Phenotypes with Breast Cancer Risk in Women: a Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 150-155. |
[8] | DOU Ziyan, QIAN Wenhong, KONG Linrun, CHEN Ye, LI Mingliang, ZHANG Jingbo. Detection Rate of Non-alcoholic Fatty Liver Disease and Its Influencing Factors: Analysis Based on the Data of 320 000 Beijing Population [J]. Chinese General Practice, 2024, 27(02): 144-149,155. |
[9] | HE Youkuan, CAO Yong, LIN Fei, OU Yuanyuan, LI Kewen, DENG Li. Platelet Changes during Extracorporeal Membrane Oxygenation in Patients with Different Modes of Support: a Retrospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 163-167. |
[10] | WANG Jie, SUN Guozhen, BAO Zhipeng, WANG Lin, GAO Min, LIU Shenxinyu, YU Tianxi, WANG Qin, GAO Rongrong. Development Trajectory and Predictors of Strength-duration Adherence to Home-based Exercise Rehabilitation among Patients with Atrial Fibrillation after Radiofrequency Catheter Ablation: a Longitudinal Study [J]. Chinese General Practice, 2024, 27(02): 168-176,183. |
[11] | DAI Yuheng, GAO Chang, LIANG Xinxiu, LU Sha, HUA Wen, ZHENG Jusheng, HU Wensheng. Association of Gut Microbiota with Hypertensive Disorders in Patients with Gestational Diabetes Mellitus [J]. Chinese General Practice, 2024, 27(02): 156-162. |
[12] | YANG Ling, DU Xueping, DONG Jianqin, DONG Yuming. Exercise Tolerance and Its Influencing Factors in Patients with Stable Coronary Artery Disease under Standardized Community Management [J]. Chinese General Practice, 2024, 27(01): 51-58. |
[13] | PAN Hongwei, LIU Li, MA Chao, DENG Guangpu, FANG Haoting, HUANG Shuwei, ZHU Hong. The Current Status and Influencing Factors of Treatment Adherence to National Chronic Disease Management Services for Hypertensive Population in a Community Healthcare Center in Guangzhou [J]. Chinese General Practice, 2024, 27(01): 59-66. |
[14] | YANG Lichao, ZENG Huatang, HU Mengzhi, WU Liqun, TIAN Qiannan, WEI Liangzhou, ZHU Jiming, LIANG Wannian. Application of Modified SEIR Model in Epidemic Prevention and Control: a Real World Study [J]. Chinese General Practice, 2024, 27(01): 118-124. |
[15] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||